Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects - PET
Study identifier:D3690C00018
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open Label Positron Emission Tomography (PET) Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects (Non Nicotine Users)
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD3480
Sex
Male
Actual Enrollment
9
Study type
Interventional
Age
20 Years - 80 Years
Date
Study Start Date: 01 Jan 2008
Primary Completion Date: 01 Aug 2008
Study Completion Date: 01 Aug 2008
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD3480 single dose, oral |
| Experimental: 2 | Radiation: 2-[18F]-F-A85380 Single dose, IV |
Contacts
Investigators
Principal Investigator
Hans-Göran , Hårdemark
Clinical Neuroscience TA AstraZeneca R&D Södertälje, Sweden
